- Home
- VRAR vs ANTX Comparison
VRAR vs ANTX Comparison
Compare VRAR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- ANTX
- Stock Information
- Founded
- VRAR 2016
- ANTX 2017
- Country
- VRAR United States
- ANTX United States
- Employees
- VRAR N/A
- ANTX N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- VRAR Technology
- ANTX Health Care
- Exchange
- VRAR Nasdaq
- ANTX Nasdaq
- Market Cap
- VRAR 29.1M
- ANTX 34.2M
- IPO Year
- VRAR 2021
- ANTX 2022
- Fundamental
- Price
- VRAR $1.63
- ANTX $1.29
- Analyst Decision
- VRAR Strong Buy
- ANTX Buy
- Analyst Count
- VRAR 1
- ANTX 2
- Target Price
- VRAR $2.62
- ANTX $2.00
- AVG Volume (30 Days)
- VRAR 315.5K
- ANTX 81.8K
- Earning Date
- VRAR 11-13-2025
- ANTX 11-12-2025
- Dividend Yield
- VRAR N/A
- ANTX N/A
- EPS Growth
- VRAR N/A
- ANTX N/A
- EPS
- VRAR N/A
- ANTX N/A
- Revenue
- VRAR $10,527,925.00
- ANTX N/A
- Revenue This Year
- VRAR $16.26
- ANTX N/A
- Revenue Next Year
- VRAR $43.33
- ANTX N/A
- P/E Ratio
- VRAR N/A
- ANTX N/A
- Revenue Growth
- VRAR 19.58
- ANTX N/A
- 52 Week Low
- VRAR $0.50
- ANTX $0.98
- 52 Week High
- VRAR $7.00
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- VRAR 51.91
- ANTX 60.03
- Support Level
- VRAR $1.40
- ANTX $1.25
- Resistance Level
- VRAR $1.78
- ANTX $1.37
- Average True Range (ATR)
- VRAR 0.17
- ANTX 0.08
- MACD
- VRAR -0.00
- ANTX -0.00
- Stochastic Oscillator
- VRAR 48.83
- ANTX 39.57
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.